Stephen D. Griffin - 01 Feb 2026 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role: President and CEO, Director
Signature: /s/ Stephen D. Griffin
Issuer symbol: ANIK
Transactions as of: 01 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2026, 18:45:54 UTC
Previous filing: 05 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Griffin Stephen D.	President and CEO, Director	32 WIGGINS AVENUE, BEDFORD	/s/ Stephen D. Griffin	03 Feb 2026	0001831125

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ANIK	Common Stock						10,671	01 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANIK	Stock Appreciation Rights	Award	$0	+310,207		$0.000000	310,207	01 Feb 2026	Common Stock	310,207	$9.23	Direct	F2, F3
transaction	ANIK	Restricted Stock Unit	Award	$0	+130,402		$0.000000	130,402	01 Feb 2026	Common Stock	130,402		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 800 shares acquired on November 14, 2025 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
F2	The Stock Appreciation Right is payable in cash, shares of common stock, or a combination thereof, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement.
F3	Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4	Each RSU represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement.